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Campylobacter jejuni is the most common zoonotic bacterium associated with human diarrhea, and chickens are considered to
be one of the most important sources for human infection, with no eﬀective prophylactic treatment available. We describe here
a prophylactic strategy using chitosan-DNA intranasal immunization to induce speciﬁc immune responses. The chitosan used
for intranasal administration is a natural mucus absorption enhancer, which results in transgenic DNA expression in chicken
nasopharynx. Chickens immunized with chitosan-DNA nanoparticles, which carried a gene for the major structural protein FlaA,
produced signiﬁcantly increased levels of serum anti-Campylobacter jejuni IgG and intestinal mucosal antibody (IgA), compared
to those treated with chitosan-DNA (pCAGGS). Chitosan-pCAGGS-ﬂaA intranasal immunization induced reductions of bacterial
expellation by 2-3 log10 and 2 log10 in large intestine and cecum of chickens, respectively, when administered with the isolated
C. jejuni strain. This study demonstrated that intranasal delivery of chitosan-DNA vaccine successfully induced eﬀective immune
response and might be a promising vaccine candidate against C. jejuni infection.
1.Introduction
Gram-negative bacterium Campylobacter is responsible for
an estimated 400 million human cases of enterocolitis
worldwide each year, making it the leading cause of bac-
terial foodborne disease and a major causative agent of
traveller’s disease. In a limited number of cases, the enteric
manifestations are followed by sequelae, such as reactive
arthritis and the life-threatening neuropathy Guillain-Barr´ e
syndrome (GBS) [1]. Two thermophilic species, C. jejuni
and C. coli, are responsible for the vast majority of human
campylobacteriosis (∼90% and ∼10%, resp.) [1]. Animals
such as chickens, cattle, pigs, sheep, and dogs may act as
asymptomatic reservoirs [2], by shedding C. jejuni in their
stools, which results in the contamination of animal food
products and surface water during slaughter and carcass
dressing [3]. Chickens, often heavily colonized with C. jejuni
without signs of pathology, are considered to be one of
the most important sources for human infection [4]. It
is generally assumed that C. jejuni-contaminated poultry
constitutes a major risk to human health.
A wide array of interventions has been developed to
reducing the carriage of C. jejuni in livestock and poultry
[5], including attempts to eliminate C. jejuni from farms
by increasing biosecurity, separating contaminated ﬂocks,
and improving hygiene during slaughter. Although these
measures undoubtedly help to control shedding of C.
jejuni in infected animals, and may reduce the number of
positive ﬂocks and the contamination level of their products,
vaccination of poultry against C. jejuni will probably be
the most eﬀective measure, and remains a major goal [6,
7]. Considering the physiology of Campylobacter and their2 Journal of Biomedicine and Biotechnology
intestinal ecological niche in poultry, conventional vaccines
have a poor performance, including inactivated vaccines
[8, 9].
Vaccines generally have a very good safety proﬁle. The
rapid advances in genomics, proteomics, and molecular
design of vaccines provide hope that an eﬀective vaccine
for Campylobacter spp. can be developed in the near future
[1, 10, 11]. In 1990, it was ﬁrst reported that intramuscular
injection of plasmid DNA in a simple saline solution could
transfect muscle cells in vivo [12]. Genetic immunization
is a novel vaccine strategy that conceptually combines
some of the most desirable attributes of standard vaccine
approaches. The immune responses comprise both cell-
mediated and humoral (antibody) components. Most recent
studiesassociatedwiththeeﬃcacyofDNAvaccineagainstC.
jejunifocusonthepotentialvaccineantigens,plasmidvector,
and DNA delivery (mucosal adjuvants). The gene ﬂaAp l a y s
an important role in the pathogenicity of C. jejuni [13]. As a
result of its biocompatibility, biodegradability, low cost, and
ability to open intercellular tight junctions, chitosan can be
used as a delivering vehicle for the mucosal vaccine and may
have an adjuvant eﬀect [14].
Here, we reported intranasal immunization of White
Leghorn chickens using chitosan-DNA nanoparticles that
carried the recombinant plasmid pCAGGS-ﬂaA for the ﬂaA
gene encoding the major structural protein FlaA of C. jejuni,
and demonstrated its eﬃcacy in inducing speciﬁc immune
responses and protection against homologous strain chal-
lenge.
2.MaterialsandMethods
2.1. Animals. White Leghorn chickens aged 1 day were
obtained from the Comparative Medicine Center of
Yangzhou University (Yangzhou University, Jiangsu, China).
Animals were housed, handled, and immunized following
approval by the institutional animal experimental commit-
tee.
2.2. Plasmids, Bacteria, and Antibodies. pCAGGS was a kind
gift from Dr. Miyazaki (Faculty of Medicine, University
of Tokyo, Japan). C. jejuni strain ALM-80 was isolated
from chicken by the Jiangsu Key Laboratory of Zoonosis,
Yangzhou University (Jiangsu, China). COS-7 cells were
ordered from Institute of Biochemistry and Cell Biology,
Chinese Academy of Sciences (Shanghai, China), and grown
in DMEM (GIBCO, Grand Island, NY, USA) supplemented
with 10% (v/v) fetal bovine serum (FBS; GIBCO). Chi-
tosan, FITC-labeled rabbit antichicken IgG, horseradish
peroxidase- (HRP-) labeled goat antichicken IgA, HRP-
labeled rabbit antichicken IgG and IgM were obtained from
Sigma(StLouis,MO,USA).Allotherchemicalsandreagents
were of analytical grade, and obtained from Sinopharm
Chemical Reagent Co., Ltd. (Shanghai, China).
2.3. Construction of pCAGGS-ﬂaA. Ap a i ro fp r i m e r sw e r e
designed to amplify gene ﬂaAo fC. jejuni that contained
XbaIa n dEcoRIs i t e s ,f o r w a r d :5  -CATCTAGAAGCATT-
TAACAAGTTCATGG-3 ,r e v e r s e :5  -TAGAATTCGTG-
TTTATCCTAAAACCCAT-3 . Ampliﬁcation was conducted
inavolumeof50μL,containing5μL10 ×buﬀer,3pMdNTP,
20pM primers, 2μL( 1 0p g )D N A ,a n d1UTaq polymerase
(Takara Diagnostics, Dalian, China). The reactions were
performedwithathermalcycler(Bio-RadLtd,Hercules,CA,
USA) using the following temperature-cycling parameters:
initial denaturation at 95
◦C for 5min, followed by 32
cycles of 1min at 94
◦C, 1min at 58
◦C, 1.5min at 72
◦C,
with a ﬁnal extension step of 5min at 72
◦C. Ampliﬁcation
generated 1935-bp DNA fragments. Eight microliters of
PCR products were separated on a 1% (w/v) agarose gel
following electrophoresis at 60V for 1.5h. Gels were stained
with ethidium bromide (0.3mg/l) and visualized under UV
illumination.A100-bpDNAladder(Promega,Madison,WI,
USA) was used as a molecular size standard.
Then, the PCR product was cloned into pGEM-T easy
vector (Sangon Biotech, Shanghai, China) to give rise to
pT-ﬂaA. The EcoRI-XbaI-restricted insert of pT-ﬂaAw a s
cloned into eukaryotic expression vector pCAGGS, and then
the recombinant vector pCAGGS-ﬂaA was constructed and
insertedinEscherichiacoli(DH5α)byelectrotransformation.
For immunization purposes, homogeneous stocks of
DNA were puriﬁed from 2.5L cultures using the Plasmid
Giga Preparation kit (Qiagen, Hilden, Germany). The DNA
preparations were quantiﬁed by optical density (OD) mea-
surements at 260nm and analyzed by 1% (w/v) agarose gel
electrophoresis.
2.4. Preparation of Chitosan-DNA Nanoparticles. The chi-
tosan/pCAGGS-ﬂaA DNA nanoparticles were synthesized by
Mao et al. [15]. In brief, a chitosan (Sigma, St Louis, MO,
USA) solution (200μg/mL in 5mM sodium acetate buﬀer,
pH 5.5), 400kD, 85% deacetylated, and a pCAGGS-ﬂaA
solution (100μg/mL in 5mM sodium sulfate solution) were
separately preheated to 50
◦C–52
◦C in parallel. Then, the
pCAGGS-ﬂaA solution was added into an equal volume of
the chitosan solution. Uniform particles were obtained by
coacervation between chitosan and DNA, and were left to
stand for at least 1h at room temperature.
2.5. Characterization of Chitosan-DNA Complexes. Freshly
prepared chitosan-DNA complexes were characterized
by morphological examination by transmission electron
microscopy (TEM). The samples were placed on a cotton
grid, allowed to sit for a few minutes and air-dried.
Then, they were negatively stained with uranyl acetate for
visualization under a transmission electron microscopy
(TEM, accelerating voltage/120kV, Philips Tecnai 12,
Holland).
Naked DNA (1μgi n2 0μLo f2 5m MN a 2SO4 solution)
or chitosan-DNA suspension (20μL, equivalent to 1μgo f
DNA)wasincubatedwith0.5UDNaseI(ﬁnalconcentration
of 28U/mL) for 15min at 37
◦C. EDTA was added to
stop the reaction to a ﬁnal concentration of 50mM. Then,
chitosan-DNA was subjected to chitosanase and lysozyme
(ﬁnal concentrations of 0.15 and 15U/mL) digestion atJournal of Biomedicine and Biotechnology 3
37
◦C for 4h. Integrity of DNA was analyzed by agarose
electrophoresis.
2.6. Gene Expression In Vitro. Two micrograms of plasmid
(Chitosan-pCAGGS-ﬂaA) was transfected into 70% con-
ﬂuent COS-7 cells covering a 6cm2 dish using a Lipofec-
tAMINE 2000 kit (Invitrogen Life Technologies, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
After 2 days incubation at 37
◦Ci n5 %C O 2, the cells were
washed with phosphate-buﬀered saline (PBS) and ﬁxed with
3% (v/v) paraformaldehyde in PBS for 20min at room
temperature. The cells were then washed three times and
permeabilized with PBS containing 0.05% (v/v) Tween 20
for 30min. After a further wash with PBS, the cells were
incubated with a 1:50 dilution of mouse antiFlaA antiserum
(from our laboratory) for 1h followed by rinsing with
PBS and incubation with ﬂuorescein isothiocyanate- (FITC-
) conjugated goat antimouse immunoglobulin G antibody
(Sigma-Aldrich, St. Louis, MO, USA) for 45min. The cells
were washed again with PBS and visualized by a ﬂuorescence
microscope (Leica Microsystems GmbH,Wetzlar, Germany).
2.7. Association Eﬃciency of Chitosan-DNA Nanoparticles.
To assay the association eﬃciency (AE) of pCAGGS-ﬂaA,
the nanoparticles suspension was ﬁrst centrifuged (Heraeus
Fresco 21; Thermo Scientiﬁc, Germany) at 30,000g, at 4◦C
for 30min. The total amount of the original pCAGGS-
ﬂaA and free (or unconjugated) pCAGGS-ﬂaA were then
analyzed using a microspectrophotometer (Biophotometer;
Eppendorf, Germany). The association eﬃciency was calcu-
lated as follows:
AE(%) =

total amount of pCAGGS-ﬂaA
total amount of pCAGGS-ﬂaA
−
total amount of free pCAGGS-ﬂaA
total amount of pCAGGS-ﬂaA

×100(%)
(1)
2.8. Vaccination of Chickens and Challenge Experiment.
One-day-old White Leghorn chickens, randomly divided
into three groups (30 per group), were immunized
intranasally with chitosan/pCAGGS-ﬂaA nanoparticles, chi-
tosan/pCAGGS,andsalinecontrol,respectively.Thesechick-
ens were immunized three times on days 1, 15, and 29 at
a dose of 150μg in 200μL (100μL each nostril). On day
42, all chickens were challenged orally with 5×107 ALM-80
strain. Three chickens were sacriﬁced every 3 days from day
45 to day 63 to harvest the small intestine, large intestine,
and cecum to calculate the number of C. jejuni ALM-80. The
method of isolation and enumeration of Campylobacter can
be found in our preliminary study [4].
2.9. Serum and Mucosal Antibody Titers to Campylobacter
Measured by Enzyme-Linked Immunosorbent Assay (ELISA).
Blood was collected after 4 and 6 weeks of primary
immunization and sera were stored at −70
◦C until they
were tested by ELISA for antibodies. The intestinal mucosal
secretion was collected at 2 and 4 weeks after booster
immunization.Theabdominalcavitywasopenedaseptically,
and the entire small intestine, including the duodenum,
jejunum, and ileum, was collected. Pancreas, connective
tissue, and fat were removed into PBS, and the intestine
was cut longitudinally and then cut into 1-cm-long sections.
The intestinal antibodies were extracted using a PBS solution
containing Tween 20 (0.05%, v/v), soybean trypsin inhibitor
(0.1mg/mL) (Sigma-Aldrich, St. Louis, MO, USA), EDTA
(0.05mg/mL), and phenylmethylsulfonyl ﬂuoride (PMSF)
(0.35mg/mL) (Sigma-Aldrich, St. Louis, MO, USA). Intesti-
nal lavage solutions were mixed with extraction solution and
shaken for 2h at 4◦C. After centrifugation at 20,000 × g
for 30min at 4◦C the supernatant was collected. Bovine
serum albumin was added to a ﬁnal concentration of 0.1%
(w/v) and samples were preserved at −20
◦C. The titer of
antibodies against Campylobacter in intestinal secretions was
measured using an indirect enzyme-linked immunosorbent
assay(ELISA)developedbylaboratoryprocedure.Brieﬂy,the
ELISA involved the following steps: (1) 96-well microtitre
plates were coated with the isolated strain ALM-80 (5 ×
105 c f u / w e l l )f o r6ha t4 2
◦C, and blocked with BSA solution
(10%, w/v) for 1h at 37
◦C, then washed with a 0.05%
(v/v) solution of Tween 20 in PBS. (2) Samples were serially
diluted and added. The plates were incubated for 2h at 37
◦C
and washed with PBS-Tween. (3) Goat antimouse IgG, IgM,
or IgA was added. The plates were incubated for 1.5h at
37
◦C and washed with PBS-Tween. (4) o-phenylenediamine
dichloride (OPD; Sigma, USA) was added to the plates at
room temperature. (5) H2SO4 (2.5M) was added to stop
the reaction 30min after addition of the substrate. (6) The
absorbance was recorded at 490nm.
2.10. Ratio of CD4+/CD8+ T Cells in Cecal Tonsil and
Spleen. To analyze the changes in T-cell composition upon
immunization, spleen and cecal tonsil of each animal
(four per group on investigation days 42 and 56) were
crushed in ice-cold PBS. The homogenates were cen-
trifuged at 300rpm for 2min at below 4◦C before the
insoluble matter settled. The isolated cells were incubated
with FITC- (ﬂuoresceinisothiocyanate-) labeled CD4 and
PE (phycoerythrin-) labeled CD8α monoclonal antibodies
(SouthernBiotechnologyAssociates,Birmingham,AL,USA)
for 30min at 37
◦C in the dark. After the cells were washed,
aliquots of 20,000 cells per sample were analyzed using a
FACSAria ﬂow cytometry system (Becton Dickinson, CA,
USA).
2.11. Statistical Analysis. The data were presented as mean ±
standard deviation. The Student t-test for comparison of
two independent samples was used to evaluate diﬀerences
between the groups (immunized group versus control).
Viable counts of bacteria were converted into logarithmic
form. For the purpose of statistical analysis, a log10 viable
count of <1.47 (limit for direct plate detection), obtained
from a sample that became positive only after enrichment,
was rated as a log10 value of 1.0. A sample which yielded no
C. jejuni growth after enrichment was rated as a log10 value4 Journal of Biomedicine and Biotechnology
of 0. Data were evaluated by multifactorial variance analysis.
P-values less than .05 were considered to be signiﬁcant,
and P-values less than .01 were considered to be highly
signiﬁcant. The ﬂow cytometry data were evaluated using
BD Bioscience’s FACS Diva software (Becton Dickinson, CA,
USA).
3. Results
3.1. Identiﬁcation of pCAGGS-ﬂaA. ﬂaA was ampliﬁed from
C. jejuni ALM-80 by PCR, and sequence analysis showed
that the sequence of ampliﬁed fragment was consistent
with that of ﬂaA published in GenBank. Recombinant
plasmids pT-ﬂaA and pCAGGS-ﬂaAw e r ec o n ﬁ r m e db yP C R
and restriction enzyme digestion. It was demonstrated that
recombinant plasmids contained the ﬂaAg e n e .
3.2. Synthesis and Characterization of Chitosan-DNA.
Chitosan-DNA complexes were synthesized when DNA
(pCAGGS-ﬂaA) solution (100μg/mL in 5mM Na2SO4)w a s
added to 0.02% (w/v) chitosan (pH 5.5) at 55
◦C during
high-speed vortexing. Uniform particles were obtained by
coacervation between chitosan and DNA. TEM observation
conﬁrmed that freshly synthesized chitosan-DNA complexes
were 80–100nm in size and nearly spherical (Figure 1), with
an association eﬃciency of 91.9%.
The ability of the chitosan/pCAGGS-ﬂaA nanoparticles
to protect pCAGGS-ﬂaAf r o mn u c l e a s ed e g r a d a t i o nw a s
evaluated by enzymatic digestion and agarose gel elec-
trophoresis. As shown in Figure 2,1 μg naked DNA was
completely degraded (lane 5) under 28U/mL DNAse I
digestion. However, even at such a high DNAse I concen-
tration, chitosan-DNA complex remained intact (lane 2).
As a control, 2μg chitosan showed entire degradation after
chitosanase and lysozyme digestion releasing most of the
DNA inside the complex (lane 3). These results suggest that
chitosan could protect DNA from markedly high concentra-
tion of DNAse I digestion. At the physiological condition
such as mucosal membrane surfaces with large quantities
but lower concentration of nucleases, this protection of DNA
by chitosan would be meaningful for the maintenance of
integration and function of DNA vaccine.
3.3. Speciﬁc Serum and Intestinal Antibody Responses. The
ability of constructed chitosan-DNA vaccine complex to
express ﬂaA in eukaryotic cells (COS-7 cell line) transfected
with pCAGGS-ﬂaA, and the negative control pCAGGS was
elucidated. At 48h post transfection, only pCAGGS-ﬂaA-
transfected cells expressed protein FlaA, which was detected
by immunoﬂuorescent assay (Figure 3).
In order to evaluate the potential utility of chitosan-DNA
immunization in inducing speciﬁc responses, 1-day-old
commercial White Leghorn chickens were vaccinated orally
with chitosan-plasmid nanoparticles at 2-week intervals.
Negative control groups included blank and CS-pCAGGS
controls.Lowtitersofspeciﬁcantibodieswereobservedinall
immunized groups at day 28. However, the titers of speciﬁc
12345 6 M
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Figure 1: TEM image of chitosan-DNA. Freshly prepared chitosan-
DNA solution was negatively stained with uranyl acetate. Scale bars
represent200nm.Thefreshlysynthesizedchitosan-DNAcomplexes
were approximately 80–100nm in size and nearly spherical under
TEM.
0.2µm
Figure 2: Protection of DNA from DNAse I digestion by chitosan.
Naked DNA and chitosan-DNA complex containing 1μgD N A
were both incubated with DNAse I for 15min at 37
◦C. Then
the reaction was stopped by adding with 0.5M EDTA. chitosan-
DNA was then subjected to chitosanase and lysozyme digestion.
Finally, all samples were run on 0.8% (w/v) agarose gel and stained
with ethidium bromide. Lane 1: chitosan-DNA; 2: chitosan-DNA +
DNAse I (28U/mL); 3: chitosan-DNA + chitosanase (0.15U/mL) +
lysozyme (15U/mL); 4: 3 + DNAse I (28U/mL); 5: DNA+ DNAse I
(28U/mL); 6: DNA (pCAGGS-ﬂaA, 4.1kb).
antibodies in the CS-pCAGGS-ﬂaA group were elevated
signiﬁcantly at day 42 (P<. 01) (Table 1).
3.4. Ratio of CD4+/CD8+ T Cells in Spleen and Cecal Tonsil.
The number of CD4+/CD8+ cells in cecal tonsil and spleen
was detected by ﬂow cytometry. Experimental data showed
that the ratio of CD4+/CD8+ T cells in the spleen of the
CS-pCAGGS-ﬂaA group was signiﬁcantly increased at dayJournal of Biomedicine and Biotechnology 5
Table 1: Immunogenicity assay of C. jejuni chitosan-DNA vaccine in chickens.
Group Titers of antibodies in serum Titers of antibodies in intestinal mucosa
Second immunization Third immunization Second immunization Third immunization
CS-pCAGGS-ﬂaA9 6 .0 ± 55.4a 426.7 ±147.8a 65.3 ±62.0b 170.7 ±73.9a
CS-pCAGGS 26.7 ±9.22 3 .3 ±18.53 4 .7 ±28.11 3 .3 ±4.6
PBS 26.7 ±9.22 3 .3 ±18.53 4 .7 ±28.12 9 .3 ±30.3
aHigh signiﬁcantly diﬀerent (P<. 01) among vaccine groups as calculated by Student’s t-test.
bSigniﬁcantly diﬀerent (P<. 05) among vaccine groups as calculated by Student’s t-test.
“CS” is the short form for chitosan.
(a) (b)
Figure 3: In vitro gene expression of chitosan-encapsulated pCAGGS-ﬂaA in COS-7 cell line by immunoﬂuorescent assay. Ability of
constructed chitosan-DNA vaccine complex to express ﬂaA in eukaryotic cells (COS-7 cell line) transfected with pCAGGS-ﬂaA( a ) ,a n d
the negative control pCAGGS (b) was evaluated. After 48h transfection, only pCAGGS-ﬂaA-transfected cells expressed protein ﬂaA, which
was detected by ﬂuorescent microscopy.
28 and day 42, and the number of CD4+ cells was greater
than the number of CD8+ cells. In the cecal tonsils, the ratio
of CD4+/CD8+ cells signiﬁcantly increased after the third
immunization compared to that in the control group. The
results indicated that the ratio of CD4+/CD8+ Tc e l l si n
the cecal tonsil and spleen of the CS-pCAGGS-ﬂaAg r o u p s
was increased after the third immunization, and the number
of CD4+ cells was greater than the number of CD8+ cells
(Table 2).
3.5. Shedding of C. jejuni in Immunized Chickens after
Challenge. After oral challenge with 5 × 107 bacteria of
strain ALM-80, the percentage of chickens with C. jejuni-
positive cloaca showed a downward trend in the vaccine
group, and bacteria were not detected at day 63. However,
the negative control groups retained a high C. jejuni-positive
ratio (Table 3).
3.6. Protection Eﬀects of Immunized Chickens after Challenge
with C. jejuni. After challenge, in vaccine group, the number
of strain ALM-80 bacteria in the small intestine, large
intestine, and cecum reached a peak from day 51 to day 57,
and then decreased. The number of bacteria was signiﬁcantly
lower than control, which showed an upward trend of
bacterial number in small intestine, large intestine and
cecum. In the CS-pCAGGS-ﬂaA group, ALM-80 was cleared
from the small intestine on day 60 (Table 4). Compared with
the negative control groups, the number of C. jejuni was
reducedby2-3log10 inthelargeintestineandby2log10 inthe
cecum when chickens were challenged with the homologous
strain (Table 4). Infection tests induced expression of that
chitosan-DNA nanoparticle vaccine that delivered ﬂaAo fC.
jejunicouldreducethenumberof C.jejuniinsmallintestine,
large intestine, and cecum eﬀectively.
4. Discussion
Vaccination has played an important role in the protection
of chickens against C. jejuni infections. However, the con-
ventional killed vaccines against C. jejuni do not completely
prevent infection and bacterial shedding [1]. Thus, an
improved vaccine and/or vaccination schedule is needed to
induce immunity in chickens. In the current study, we have
developed chitosan/pCAGGS-ﬂaA nanoparticles to inhibit
Campylobacter jejuni in a White Leghorn model, which is a
common layer chicken breed in China.
DNA vaccine can provide eﬀective immunostimulation
in terms of humoral and cell-mediated responses, therefore
overcoming the inﬂuence of maternal antibody. Meanwhile,
DNA vaccine has broad prospects in the prevention and
treatment of bacterial, viral, parasitic, and other infections
[12]. The strong immunogenicity and cross-protection of
antigen genes are the prerequisites for constructing DNA
vaccines, which is a good strategy to improve their immuno-
logical eﬀects. For C. jejuni, adhesion to, invasion, and6 Journal of Biomedicine and Biotechnology
Table 2: Ratio of CD4+/CD8+ T cells in spleen and cecal tonsil of immunized chickens.
Group Ratio
a of CD4+/CD8+ T cells in spleen Ratio
a of CD4+/CD8+ T cells in cecal tonsil
Second immunization Third immunization Second immunization Third immunization
CS-pCAGGS-ﬂaA1 .34 ±0.53b 1.54 ±0.23b 0.98 ±0.17 1.94 ±0.21b
CS-pCAGGS 0.63 ±0.22 0.94 ±0.22 0.92 ±0.26 1.29 ±0.18
PBS 0.62 ±0.05 1.00 ±0.08 1.17 ±0.30 1.27 ±0.30
aValues are means ± standard deviations (four samples per group) for ratio of CD4+/CD8+ T cells treated with CS-pCAGGS-ﬂaA and CS-pCAGGS or PBS.
bSigniﬁcantly diﬀerent (P<. 05) among vaccine groups as calculated by Student’s t-test.
Table 3: Average positive rate of swab specimens of White Leghorn chickens challenged with strain ALM-80.
Group Average positive rate of swab specimens after oral challenge
7 days 14 days 21 days
CS-pCAGGS-ﬂaA 47.62% (10/21) 30.77% (4/13)
a 0.00% (0/9)
a
CS-pCAGGS 47.62% (10/21) 53.33% (8/15) 44.44% (4/9)
PBS 42.86% (9/21) 53.33% (8/15) 55.56% (5/9)
aSigniﬁcantly diﬀerent (P<. 05) among vaccine groups as calculated by Student’s t-test.
colonization of host intestinal cells require the participation
of ﬂagellin, which is essential for C. jejuni to adhere to
host cells. Therefore, it is a key step in the process of
host infection [16]. In our study, based on the analysis
of virulence genes mainly carried by isolated strains, we
selected ﬂagellin gene ﬂaA, which is closely involved in the
infection process, as a protective antigen gene to construct a
DNA vaccine. The ﬂagella gene plasmid DNA constructed by
Wyszy´ nska et al. can reduce the number of Campylobacter
by 2 log2 [17]. Widders et al. found that titers of IgG
and IgM in serum and IgG in intestinal mucosa were high
after primary immunization with intraperitoneal injection
and secondary immunization with intraperitoneal injection
or oral administration of puriﬁed ﬂagellin protein, and
results indicated that immunization could reduce the level
of intestinal infection with C. jejuni by 1-2 log2 [18].
DNAvaccineexpressionvectorswithdiﬀerentpromoters
have signiﬁcant impacts on expression of immunogenic
genes [19]. The plasmid vector pCAGGS contains chicken β-
actin promoter and cytomegalovirus enhancer of eukaryotic
expression plasmid, therefore, the level of pCAGGS will
be signiﬁcantly high after transient transfection of most
cell lines [20, 21]. Many studies have suggested that the
expression eﬃciency of pCAGGS is high, therefore, it is
presentlybeingappliedwidely[22].Ontheotherhand,using
chitosan, a natural bioadhesive material, as a gene carrier
turned out to be an ideal way to stimulate the immune
system. The aminoglucose and DNA can form complexes
(polyplexes) via their electrostatic interaction. Chitosan can
condense DNA into relatively compact nanoparticles and
these can overcome physiological barriers when drugs are
absorbed by the mucosa and arrive at the submucosal
lymphoid tissue by endocytotic channels. The advantages
of chitosan nanoparticles as gene vectors are as follows.
(i) They can protect DNA from degradation in vivo [15].
(ii) Positively charged nanoparticles together with negatively
charged mucosal cells and sialic acid can generate stronger
electrostatic interactions and prolong the reaction time
between vaccines and the mucosa, and increase vaccine
uptake [23]. The preparation conditions of chitosan-DNA
nanoparticles are mild, without using organic solvents,
which solves the problem of DNA destruction by solvent
residues. Chitosan is regarded as a potential nonviral gene
carrier. Mao et al. were the ﬁrst to combine DNA vaccine
and chitosan to create a chitosan-DNA nanovaccine, which
successfullygeneratedimmunologicalprotectioninamurine
model of peanut allergy, and proved to be an eﬀective oral
gene delivery system [15]. In our study, high encapsulation
eﬃciency was obtained (>90%), as demonstrated by elec-
trophoresisandelectronmicroscopy.Protectiontestsshowed
that chitosan-DNA nanoparticle vaccine that contained ﬂaA
of C. jejuni reduced eﬀectively colonization of C. jejuni in the
small intestine, large intestine, and cecum.
At present, investigation of the protective immune
responses against C. jejuni is at the initial stage [24]. Campy-
lobacter vaccine can induce signiﬁcant immune protection
against experimental infection of mice, ferrets, rabbits, or
primates, and might relieve or eliminate clinical symptoms
in these animals [25]. Nevertheless, vaccines have diﬀerent
eﬀects on mammals and chickens, which needs to be
consideredwhenresearchisconductedusingchickenmodels
of colonization of the intestinal tract.
In addition, since ﬂaAo fC. jejuni is highly variable
[26], it is interesting to assess the protective eﬃcacy of the
chitosan/pCAGGS-ﬂaA nanoparticles against challenge with
other C. jejuni strains in future studies. What’s more, they
need to replicate more eﬃciently in broilers by optimizing
the immunization strategy.
5. Conclusions
This study demonstrated that intranasal delivery of
chitosan-DNA vaccine successfully induced eﬀectiveJournal of Biomedicine and Biotechnology 7
Table 4: The number of C. jejuni in small intestine, large intestine, and cecum after oral challenge.
Organ Group CFU (CFU/g)
3 days 6 days 9 days 12 days 15 days 18 days 21 days
Small intestine
19 .2 ×103 3.4 ×103 6.0 ×102 8.2 × 103 1.9 ×103 00
23 .5 ×102 7.6 ×102 1.2 ×102 1.4 × 104 5.9 ×104 6.3 ×103 7.6 ×104
32 .0 ×103 6.3 ×102 7.3 ×102 1.7 × 103 1.2 ×105 2.9 ×104 3.8 ×104
Large intestine
14 .6 ×105 1.1 ×106 1.5 ×107 4.8 × 106 2.9 ×106 3.5 ×106 6.5 ×105
25 .4 ×107 3.2 ×107 2.2 ×107 1.1 × 107 1.8 ×108 4.2 ×107 1.5 ×108
34 .7 ×107 2.1 ×107 2.2 ×107 9.3 × 107 3.5 ×108 3.2 ×107 1.8 ×107
Cecum
12 .2 ×106 4.5 ×106 2.8 ×107 2.9 × 107 3.7 ×107 3.0 ×107 1.2 ×107
22 .7 ×108 1.8 ×108 7.4 ×108 2.4 × 108 1.9 ×108 2.6 ×109 2.3 ×109
34 .3 ×108 2.2 ×108 4.0 ×108 4.0 × 108 2.6 ×108 4.7 ×109 2.7 ×109
Group 1: CS-pCAGGS-ﬂaAg r o u p .
Group 2: CS-pCAGGS group.
Group 3: PBS group.
immune response and might be a promising vaccine
candidate against C. jejuni infection.
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